$1.08
-0.02 (-1.82%)
Open$1.05
Previous Close$1.10
Day High$1.16
Day Low$1.03
52W High$25.65
52W Low$16.65
Volume—
Avg Volume412.5K
Market Cap9.42M
P/E Ratio—
EPS$-0.95
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,900.0% upside
Current
$1.08
$1.08
Target
$21.60
$21.60
$19.68
$21.60 avg
$29.43
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.93M | 3.80M | 4.24M |
| Net Income | 750.9K | 985.2K | 805.1K |
| Profit Margin | 19.1% | 25.9% | 19.0% |
| EBITDA | 1.30M | 1.34M | 1.32M |
| Free Cash Flow | 898.9K | 1.13M | 1.05M |
| Rev Growth | -2.1% | +24.5% | -6.6% |
| Debt/Equity | 0.84 | 1.00 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |